Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study

• Published in: Pharmacotherapy Vol. 19; no. 9; p. 1050
• Main Authors: Falloon, J, Sargent, S, Piscitelli, S C, Bechtel, C, LaFon, S W, Sadler, B, Walker, R E, Kovacs, J A, Polis, M A, Davey, Jr, R T, Lane, H C, Masur, H
• Format: Journal Article
• Language: English
• Published: United States 01.09.1999
• Subjects: Adult; AIDS-Related Opportunistic Infections - metabolism; AIDS-Related Opportunistic Infections - prevention & control; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Antifungal Agents - pharmacokinetics; Atovaquone; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Naphthoquinones - administration & dosage; Naphthoquinones - adverse effects; Naphthoquinones - pharmacokinetics; Pneumonia, Pneumocystis - prevention & control; Trimethoprim, Sulfamethoxazole Drug Combination - pharmacokinetics

To evaluate the pharmacokinetics and safety of atovaquone suspension in volunteers infected with the human immunodeficiency virus ((HIV). Open-label, nonrandomized study. Two clinical research centers. Twenty-two HIV-infected volunteers with a median CD4 cell count of 37 cells/mm3. Patients received...